**5. References**

Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M. , et al. (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. *Nat Biotechnol* 25: pp. 903-910.

Rodent Models with Humanized Liver: A Tool to Study Human Pathogens 149

Kneteman, N.M., Howe, A.Y., Gao, T., Lewis, J., Pevear, D. , et al. (2009) HCV796: A

Kneteman, N.M., Weiner, A.J., O'Connell, J., Collett, M., Gao, T. , et al. (2006) Anti-HCV

Kremsdorf, D., Brezillon, N. (2007) New animal models for hepatitis C viral infection and

Kurbanov, F., Tanaka, Y., Chub, E., Maruyama, I., Azlarova, A. , et al. (2008) Molecular

Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O., Strandvik, B. (1992) Treatment of

Lutgehetmann, M., Bornscheuer, T., Volz, T., Allweiss, L., Bockmann, J.H. , et al. (2011)

Lutgehetmann, M., Volz, T., Kopke, A., Broja, T., Tigges, E. , et al. (2010) In vivo

Matsumura, T., Hu, Z., Kato, T., Dreux, M., Zhang, Y.Y. , et al. (2009) Amphipathic DNA

Mazier, D., Beaudoin, R.L., Mellouk, S., Druilhe, P., Texier, B. , et al. (1985) Complete

Meuleman, P., Albecka, A., Belouzard, S., Vercauteren, K., Verhoye, L. , et al. (2011a)

Meuleman, P., Catanese, M.T., Verhoye, L., Desombere, I., Farhoudi, A. , et al. (2011b) A

Meuleman, P., Hesselgesser, J., Paulson, M., Vanwolleghem, T., Desombere, I. , et al. (2008)

Meuleman, P., Libbrecht, L., De Vos, R., de Hemptinne, B., Gevaert, K. , et al. (2005)

Meuleman, P., Libbrecht, L., Wieland, S., De Vos, R., Habib, N. , et al. (2006) Immune

Mikolajczak, S.A., Sacci, J.B., Jr., De La Vega, P., Camargo, N., VanBuskirk, K. , et al. (2011)

chimeric mice. *Gastroenterology* 140: pp. 2074-2083, 2083 e2071-2072.

pathogenesis studies. *World J Gastroenterol* 13: pp. 2427-2435.

virus strain RF1\_2k/1b. *J Infect Dis* 198: pp. 1448-1456.

closed circular DNA in mice. *Hepatology* 52: pp. 16-24.

and viral spread in vitro and in vivo. *Hepatology*.

mouse chimera. *Hepatology* 41: pp. 847-856.

with hepatitis C virus. *Hepatology* 49: pp. 745-752.

application. *Hepatology* 43: pp. 1346-1353.

dioxygenase. *Lancet* 340: pp. 813-817.

137: pp. 673-681.

48: pp. 1761-1768.

80: pp. 2797-2807.

*Chemother* 55: pp. 5159-5167.

440-442.

selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected

therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical

epidemiology and interferon susceptibility of the natural recombinant hepatitis C

hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate

Hepatitis B virus limits response of human hepatocytes to interferon-alpha in

proliferation of hepadnavirus-infected hepatocytes induces loss of covalently

polymers inhibit hepatitis C virus infection by blocking viral entry. *Gastroenterology*

development of hepatic stages of Plasmodium falciparum in vitro. *Science* 227: pp.

Griffithsin Has Antiviral Activity against Hepatitis C Virus. *Antimicrob Agents* 

human monoclonal antibody targeting SR-BI precludes hepatitis C virus infection

Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. *Hepatology*

Morphological and biochemical characterization of a human liver in a uPA-SCID

suppression uncovers endogenous cytopathic effects of the hepatitis B virus. *J Virol*

Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites. *Cell Microbiol* 13: pp. 1250-1260. Moreno, A., Perignon, J.L., Morosan, S., Mazier, D., Benito, A. (2007) Plasmodium

falciparum-infected mice: more than a tour de force. *Trends Parasitol* 23: pp. 254-259.


Bissig, K.D., Le, T.T., Woods, N.B., Verma, I.M. (2007) Repopulation of adult and neonatal

Brezillon, N., Brunelle, M.-N., Massinet, H., Giang, E., Lamant, C., DaSilva, L., Berissi, S.,

Dandri, M., Burda, M.R., Gocht, A., Torok, E., Pollok, J.M. , et al. (2001a) Woodchuck

Dandri, M., Burda, M.R., Torok, E., Pollok, J.M., Iwanska, A. , et al. (2001b) Repopulation of

Dandri, M., Burda, M.R., Zuckerman, D.M., Wursthorn, K., Matschl, U. , et al. (2005) Chronic

Dandri, M., Volz, T.K., Lutgehetmann, M., Petersen, J. (2005) Animal models for the study of

Fournier, C., Sureau, C., Coste, J., Ducos, J., Pageaux, G. , et al. (1998) In vitro infection of

Greenwood, B.M., Fidock, D.A., Kyle, D.E., Kappe, S.H., Alonso, P.L. , et al. (2008) Malaria: progress, perils, and prospects for eradication. *J Clin Invest* 118: pp. 1266-1276. Gripon, P., Diot, C., Theze, N., Fourel, I., Loreal, O. , et al. (1988) Hepatitis B virus infection

Grompe, M., al-Dhalimy, M., Finegold, M., Ou, C.N., Burlingame, T. , et al. (1993) Loss of

Grompe, M., Lindstedt, S., al-Dhalimy, M., Kennaway, N.G., Papaconstantinou, J. , et al.

murine model of hereditary tyrosinaemia type I. *Nat Genet* 10: pp. 453-460. He, Z., Zhang, H., Zhang, X., Xie, D., Chen, Y. , et al. (2010) Liver xeno-repopulation with

Heckel, J.L., Sandgren, E.P., Degen, J.L., Palmiter, R.D., Brinster, R.L. (1990) Neonatal

Joyce, M.A., Walters, K.A., Lamb, S.E., Yeh, M.M., Zhu, L.F. , et al. (2009) HCV induces

Kamiya, N., Iwao, E., Hiraga, N., Tsuge, M., Imamura, M. , et al. (2010) Practical evaluation

Katoh, M., Sawada, T., Soeno, Y., Nakajima, M., Tateno, C. , et al. (2007) In vivo drug

phenotype of lethal albino mice. *Genes Dev* 7: pp. 2298-2307.

immunosuppression. *Am J Pathol* 177: pp. 1311-1319.

an NS3-4A protease inhibitor. *J Gen Virol* 91: pp. 1668-1677.

B Virus in Humanized Alb-uPA/SCID Mice. *PLoS ONE*. Online.

repopulation after cryopreservation. *Hepatology* 34: pp. 824-833.

liver repopulation with tupaia hepatocytes. *J Hepatol* 42: pp. 54-60.

HBV replication and its variants. *J Clin Virol* 34 Suppl 1: pp. S54-62.

104: pp. 20507-20511.

*Hepatology* 33: pp. 981-988.

*Virol* 79 ( Pt 10): pp. 2367-2374.

62: pp. 4136-4143.

62: pp. 447-456.

mice. *PLoS Pathog* 5: pp. e1000291.

humanized liver. *J Pharm Sci* 96: pp. 428-437.

mice with human hepatocytes: a chimeric animal model. *Proc Natl Acad Sci U S A*

Belghiti, J., Hannoun, L., Puerstinger, G., Wimmer, E., Neyts, J., Hantz, O., Soussan, P., Morosan, S., Kremsdorf, D. (2011) Antiviral Activity of Bay 41-4109 on Hepatitis

hepatocytes remain permissive for hepadnavirus infection and mouse liver

mouse liver with human hepatocytes and in vivo infection with hepatitis B virus.

infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after

adult normal human hepatocytes in primary culture by hepatitis C virus. *J Gen* 

of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. *J Virol*

fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction

(1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a

human hepatocytes in Fah-/-Rag2-/- mice after pharmacological

bleeding in transgenic mice expressing urokinase-type plasminogen activator. *Cell*

oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA

of a mouse with chimeric human liver model for hepatitis C virus infection using

metabolism model for human cytochrome P450 enzyme using chimeric mice with


**9** 

**Liver Parenchyma Regeneration in Connection** 

Liver surgery underwent enormous evolution after development and introduction of new technical skills in surgical praxis. Nevertheless many patients with primary or secondary liver malignancies are not indicated to radical surgical therapy that could reach complete remission of malignant disease because the frontiers of liver surgery are limited today by the functional reserves of remnant parenchyma. The main argument to non surgical treatment is increased risk of acute liver failure after extended liver resection, where retained liver parenchyma is to small to sustain the liver functions (Abdalla, 2001). Portal vein embolization (PVE) can multiply the future liver remnant volume (FLRV) in spite of affection of only one of liver lobes by malignant diseases (Makuuchi, 1984, Makuuchi, 1990, Harada, 1997). This procedure was performed firstly in 1984 by Makuuchi (Abdalla, 2001, Makuuchi, 1984, Makuuchi, 1990). PVE of portal branch of with malignancy afflicted liver lobe initiates compensatory hypertrophy of contralateral non-occluded lobe. The occluded lobe underlies atrophy. The compensatory hypertrophy is supposed to be stimulated by increased flow of portal blood, that contains hepatotrophic substances (Kusaka, 2004, Azoulay, 2000). Liver resection after PVE is performed only in 63-96% of patients (Kokudo, 200, Stefano, 2005, Lagasse, 2000). The main reason for this resolution is unsuccessful hypertrophy of FLRV or progression of malignancy. Liver resection after PVE is performed only in 63-96% of patients (Azoulay, 200, Kokudo, 2001, Stefano, 2005). The main reason for

this resolution are unsuccessful hypertrophy of FLRV or progression of malignancy.

\* Vladislav Treska1, Hynek Mirka2, Ondrej Vycital1, Jan Bruha1, Pavel Pitule1, Jana Kopalova1, Tomas Skalicky1, Alan Sutnar1, Jan Benes3, Jiri Kobr4, Alena Chlumska5, Jaroslav Racek6

*Teaching Hospital and Medical School Pilsen, Charles University Prague, Czech Republic* 

**1. Introduction** 

and Ladislav Trefil6 *1Department of Surgery, 2Department of Radiology,* 

*5Institute of Pathology,* 

*3Department of Anaesthesiology and Resuscitation, 4Department of Pediatrics,* 

*6Institute of Biochemistry and Haemathology,* 

**with Extended Surgical Procedure –** 

*Teaching Hospital and Medical School Pilsen, Charles University Prague,* 

**Experiment on Large Animal** 

Vaclav Liska et al.1,\* *1Department of Surgery* 

*Czech Republic* 

